Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft

14 Mar 2022

Abstract excerpt

Chordomas are rare neoplasms characterized by a high recurrence rate and a poor long-term prognosis. Considering their chemo-/radio-resistance, alternative treatment strategies are strongly required, but their development is limited by the paucity of relevant preclinical models. Mutations affecting genes of the SWI/SNF complexes are frequently found in chordomas, suggesting a potential therapeutic effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Tumor Diagnosis and Treatments
Share to Chromatin Remodeling and Cancer
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35326637
DOI: 10.3390/cancers14061486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma XenograftPMID 35326637Read ↗

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.Semantic proximity Read ↗

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapySemantic proximity Read ↗

Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and RadiotherapySemantic proximity Read ↗

Dysregulated Epigenetics of Chordoma: Prognostic Markers and Therapeutic TargetsSemantic proximity Read ↗

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.Semantic proximity Read ↗

Emerging target discovery and drug repurposing opportunities in chordomaSemantic proximity Read ↗

Targeting epigenetics in sarcomas through EZH2 inhibitionSemantic proximity Read ↗

Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle PathwaySemantic proximity Read ↗

Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical OutcomesSemantic proximity Read ↗

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasSemantic proximity Read ↗

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read ↗

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.